Literature DB >> 7557895

Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.

D J Flavell1, S Cooper, K Okayama, L Emery, S U Flavell.   

Abstract

We have investigated the cytotoxic performance of two different anti-CD7/anti-saporin BsAb's (HB2 x DB7-18 and Q1.1), three anti-CD38/anti-saporin BsAb's (OKT10 x RabSap, OKT10 x DB7-18 and Q4.1) and an anti-CD7 (HB2-Sap) and anti-CD38-saporin (OKT10-Sap) immunotoxin for delivering the ribosome inactivating protein (rip) to the human T-cell acute lymphoblastic leukemia cell line HSB-2. In the case of CD7 as target molecule the immunotoxin outperformed both anti-CD7 BsAb's being six times more effective than HB2 x DB7-18 and 98 times more so than Q1.1 at effectively inhibiting protein synthesis in a dose dependent manner. The chemically constructed HB2 x DB7-18 BsAb was more effective at inhibiting protein synthesis and cell growth in target HSB-2 cells in a dose dependent manner than the quadroma produced BsAb Q1.1. Both BsAb demonstrated a prozone effect used at concentrations above 0.1 nM though this was more pronounced for Q1.1 than for HB2 x DB7-18. The prozone effect was partially though not completely reversed by increasing the concentration of saporin in the system. In the case of CD38 as target molecule the anti-CD38 IT OKT10-Sap performed poorly, never actually achieving its IC50. Two BsAb's constructed with monoclonal anti-saporin Fab arms each recognizing a different epitope on the saporin molecule also performed poorly. In contrast the BsAb OKT10 x RabSap constructed with Fab derived from a rabbit polyclonal anti-saporin antiserum performed in a dose dependent manner achieving its IC50 at a concentration of 1.3 nM. This BsAb also exhibited a prozone effect. These results exemplify the importance of cross linking adjacent target molecules on the cell surface in order to achieve effective delivery of saporin to the cell interior.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557895     DOI: 10.1002/hon.2900130403

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  3 in total

1.  Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.

Authors:  Lisa Winterroth; Johanna Rivera; Antonio S Nakouzi; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

Review 2.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

Review 3.  Targeted Therapy With Immunoconjugates for Multiple Myeloma.

Authors:  Wassilis S C Bruins; Sonja Zweegman; Tuna Mutis; Niels W C J van de Donk
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.